^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
Excerpt:
...The tumor harbors epidermal growth factor receptor (EGFR) mutations(include 19del, L858R, T790M, G719X, L861Q, S768I, 20 A763-Y764ins), and at least concurrent with TP53 6....
Trial ID:
Source:
Title:
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Excerpt:
...- EGFR T790M positive...
Trial ID:
Less C2 evidence
Source:
Title:
Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
Published date:
05/05/2022
Excerpt:
The overall response rate (ORR) was higher in the combination group than in the osimertinib-alone group (70.0% vs. 43.8%), and the OS (12.8% ± 7.7% vs. 45.4% ± 12.0%; p = 0.038) and PFS (37.3% ± 11.9% vs. 55.3% ± 14.3%; p = 0.045) were also significantly improved in patients who underwent osimertinib plus bevacizumab....Concomitant use of bevacizumab and osimertinib in NSCLC patients with EGFR T790M mutation may have potential therapeutic effect than osimertinib alone.
DOI:
10.1007/s40261-022-01145-7
Source:
Title:
VP3_2021 - A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Published date:
09/13/2021
Excerpt:
...combined Osi/Bev versus Osi in pts with NSCLC with EGFR-mt (exon 19 del or L858R) and T790M-mt at progression on prior EGFR TKI...the median PFS was 15.4m (95% CI 9.2-18.0) and 12.3m (6.2-17.2) (PFS events: 64 & 65) in the Osi/Bev and Osi arm respectively (HR 0.96; 0.68- 1.37; p=0.83). Median OS was 24.0m (17.8-32.1) in Osi/Bev and 24.3m (16.9-37.0) in Osi arm (deaths: 46 & 43) (HR 1.03; 0.67-1.56; p=0.91). ORR was 55% in both arms.
Trial ID:
Source:
Title:
No extra PFS benefit with bevacizumab plus osimertinib in EGFR-mutated NSCLC
Published date:
01/20/2021
Excerpt:
CONTRADINCTING EVIDENCE: Adding bevacizumab to osimertinib therapy does not improve progression-free survival (PFS) for patients with advanced non-small-cell lung cancer (NSCLC) harboring an EGFR T790M mutation, phase 2 study data suggest.
Source:
Title:
P76.93 The Efficacy of Second-Line Osimertinib Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Published date:
01/12/2021
Excerpt:
Most of 221 patients had T790M mutation (95.5%). Further analysis of 33 patients receiving Bevacizumab combined with Osimertinib showed that among the second-line Bev+OSI patients, CR + PR was 18.2%...PFS of Bev+OSI and OSI monotherapy with propensity score in a ratio of 1:1, the PFS of the two groups was 420 days v.s. 336 days (P < 0.05)....patients with T790M-positive advanced non–small-cell lung cancer who progressed following first-line EGFR-TKI therapy Bevacizumab combined with Osimertinib may further improve the PFS.
Source:
Title:
Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
Published date:
03/14/2022
Excerpt:
...we investigated the antitumor efficacy of osimertinib plus bevacizumab in an LM xenograft model using the H1975 (EGFR exon20 T790M and exon21 L858R) cell line.…indicated that combined osimertinib with bevacizumab may exhibit a synergistic effect in EGFR-mutant LM model possibly by modulating the level of E-cadherin.
DOI:
https://doi.org/10.1186/s12967-022-03331-9
